The perfect match: Aortic valve sizing to maximize hemodynamic performance and survival
<h2>Abstract</h2><h3>Objective</h3> We assessed the value of using a size ratio of implanted valve opening diameter to native annular diameter to determine postoperative hemodynamics and survival after surgical aortic valve replacement. <h3>Methods</h3> In total, 1519 patients from 3 trials had a preoperative computed tomography scan. A size ratio was created using the implanted valve's Ebels' prosthetic valve−derived effective diameter (ED) and the patient's computed tomography perimeter−derived native annular diameter (CTD). Restricted cubic spline curves showed the association between size ratio and hemodynamic performance. Patients were divided into 3 ratio groups: <80%, 80% to 90%, and >90%. Hemodynamic performance was evaluated yearly for 5 years. Multivariable proportional hazard regression examined the association between size ratio and 5-year survival. <h3>Results</h3> Mean valve gradient, peak velocity, effective orifice area (EOA), indexed EOA, dimensionless velocity index, and prosthesis-patient mismatch were significantly better advancing from the 80% to the 90% groups (<i>P</i> < .001). The >90% group had a single-digit mean valve gradient, peak velocity ≤2.0 m/s, EOA ≥2.0 cm<sup>2</sup>, indexed EOA ≥1.0 cm<sup>2</sup>/m<sup>2</sup>, dimensionless velocity index ≥0.5, and no prosthesis-patient mismatch ≥85% at 1 and 5 years. Size ratio was an independent predictor of mortality with survival benefit through 5 years (80%-90% vs <80%, hazard ratio, 0.752; 95% confidence interval, 0.611-0.927, <i>P</i> = .008; >90% vs <80%, hazard ratio, 0.712; 95% confidence interval, 0.506-1.001, <i>P</i> = .05). <h3>Conclusions</h3> An ED/CTD size ratio >90% is associated with optimal postoperative hemodynamic performance and improved 5-year survival. Preoperative ED/CTD ratio provides the ideal implanted valve size and helps determine if annular enlargement is necessary.
Authors
- Bo Yang (ORCID: https://orcid.org/0000-0002-2158-9155)
- Julie A. Linick
- Robert B. Hawkins (ORCID: https://orcid.org/0000-0002-3959-8201)
- Shinichi Fukuhara (ORCID: https://orcid.org/0000-0002-7898-5159)
- Himanshu J. Patel (ORCID: https://orcid.org/0000-0001-7639-2416)
- Barbara C.S. Hamilton (ORCID: https://orcid.org/0000-0002-5498-3378)
- Stanley Chetcuti
- Michael J. Reardon (ORCID: https://orcid.org/0000-0002-2880-6132)
- Sachin S. Goel (ORCID: https://orcid.org/0000-0001-6041-3876)
- Michael J. Boulware
- Shuzhen Li (ORCID: https://orcid.org/0000-0002-8336-092X)
- Gorav Ailawadi
- G. Michael Deeb
- Mikhale Grundtner
Institutions
- Houston Methodist (US)
- University of Michigan (US)
- Medtronic (Ireland) (IE)
Publication Details
- Journal
- JTCVS structural and endovascular.
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1016/j.xjse.2025.100088
- Citations
- 1
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39